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Results of robotic radical prostatectomy in the hands of
surgeons without previous laparoscopic radical prostatectomy
experience*
Abdullah Erdem CANDA, Ali Fuat ATMACA, Ziya AKBULUT, Erem ASİL, Metin KILIÇ,
Abidin Egemen İŞGÖREN, Mevlana Derya BALBAY

Aim: We report our initial experience related with robot-assisted laparoscopic radical prostatectomy (RALRP)
performed by a urologic surgeon without previous laparoscopic radical prostatectomy (LRP) experience.
Materials and methods: The data of the first 70 patients who underwent RALRP between February 2009 and February
2010 are presented.
Results: Mean console time was 214 ± 55.5 min with pelvic lymph node dissection (LND) in 14 patients. Mean
intraoperative blood loss was 215 ± 227.3 cc. Fourteen patients had positive surgical margins: pT3 (n = 12) and pT2 (n
= 2). Lodge drains and urethral catheters were removed at a mean of 2.9 ± 2.7 and 11.6 ± 5.9 days, respectively. Fortythree of 58 patients (82.9%) had urinary control at the 3-month follow-up. Regarding the patients with preoperative IIEF
scores ≥ 19 (mean: 47.6 ± 17.0, n = 46), mean IIEF score was 45.3 ± 9.9 (n = 11) at the 9-month follow-up. Regarding
patients with preoperative IIEF scores of 13-18 (mean: 16.3 ± 1.1, n = 6), mean IIEF score was 17.0 ± 3.5 (n = 3) at the
9-month follow-up. One patient who could not tolerate CO2 insufflation was switched to open surgery due to deep
acidosis development. Rectal injury occurred in 1 patient and was repaired robotically without postoperative problems.
Conclusion: Previous LRP experience is not essential in order to perform RALRP, which can be learned and performed
easily. Additionally, short-term surgical results and pathological outcomes of RALRP are excellent and satisfactory,
respectively.
Key words: Robot assisted, laparoscopic, radical prostatectomy, prostate cancer, outcomes

Introduction
Radical prostatectomy (RP) provides long-term
cancer control in patients with localized prostate
cancer (PCa) (1). Robot-assisted laparoscopic radical
prostatectomy (RALRP) has increasingly become
a preferred treatment of choice both by patients
and urologists since its introduction in 2001 (2).
To date several authors with previous experience in
laparoscopic RP (LRP) have reported the outcomes
of their series of RP by using the da Vinci surgical

system (Intuitive Surgical, Sunnyvale, CA, USA) (36).
We hypothesized that previous experience in LRP
is not essential before starting RALRP. However,
complete understanding of the 3-dimensional
anatomy of the prostate and its surroundings is a
must.
Herein, we report our initial experience of RALRP
performed by one of us (MDB) without any previous
experience of LRP.
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Materials and methods
Between February 2009 and February 2010, we
performed 70 RALRP procedures at our institution.
All patients in our series were operated on by one of
us (MDB) using a da Vinci-S 4-arm surgical robot
(Intuitive Surgical) with no previous experience of
LRP but great experience in open RP and additional
experience in upper urinary tract laparoscopic
surgery.
For our initial experience, patients with a previous
history of abdominal surgery were excluded (Table
1).
Operative technique and surgical steps
We used a transperitoneal approach patient in the
steep (30°) Trendelenburg position. A total of 5 ports
were placed, including a 12-mm port for the camera,
three 8-mm ports for the robotic arms, and a 12-mm
port for bedside assistance.
We placed the 4th arm on the right side of the
patient and controlled it with the right hand. The
procedure was started by making an incision on the
anterior peritoneal covering of the Douglas pouch,
approximately 1 cm proximal to its reflection on the
rectum. Vasa deferentia and seminal vesicles were
dissected and Denonvilliers’ fascia was opened.
Anterior attachments between the bladder and
abdominal wall were taken down by monopolar
scissors and the Retzius space was entered. After
defatting, the endopelvic fascia was opened and
levator ani muscle fibers were dissected off all the way
along the lateral prostatic fascia.
The dorsal venous complex (DVC) was identified
and suture tied distal to the apex of the prostate. Next,
the detrusor apron overlying the prostate anteriorly
was identified and dissected superiorly until the
entrance of the urethra into the prostate at the bladder
base was observed where its anterior wall was incised.
The posterior neck area was checked for the presence
of the median lobe and incision of the urethra at this
level was completed. Subsequently, high anterior
release and neurovascular bundle (NVB) dissections
were carried out. The procedure was completed after
division of DVC and vesicourethral anastomosis
with the use of the van Velthoven technique with or
without posterior Rocco construction.

Bilateral extended pelvic lymphadenectomy was
performed in patients who had an intermediate- or
high-risk for pelvic lymph node (LN) metastasis
according to Partin’s tables (7) with an at least 6% risk
of LN involvement by PCa (Table 2).
The prostate was extracted from the abdomen
after the enlargement of the supra-umbilical port site
following inclusion into the endobag. An abdominal
drain was left in place. Thereafter, we grossly
examined the prostate for any suspicious areas.
Patients were discharged after tolerating an oral
diet and sufficient ambulation following removal of
the lodge drains. At the end of the first postoperative
week, cystography was carried out by filling the
bladder with 200 cc of diluted contrast material. If no
leakage was seen, the urethral catheter was removed.
Otherwise, the urethral catheter was kept for another
week for another cystography. Continence was
defined as either the use of no pads or use of one
protective pad for precautionary measures as a safety
pad. Immediate continence was evaluated following
removal of the urethral catheter after cystography
was performed. Potency was defined as the ability to
achieve penetration and complete intercourse with
or without the use of oral type-5 phosphodiesterase
(PDE-5) inhibitors. Patient characteristics with
preoperative measures are summarized in Table 1.
Results
Operative measures, oncologic outcomes, functional
outcomes, and quality of lives of patients who
underwent RALRP at our institution are summarized
in Tables 2, 3, and 4. Currently, of the 70 patients, 10,
58, 41, and 1 had completed 1-, 3-, 6-, and 12-month
evaluations, respectively.
We had to switch to open surgery in only one
patient (1.4%), solely because of deep acidosis, who
could not tolerate further intra-abdominal CO2
insufflation. Rectal injury occurred in one patient
(1.4%), which was repaired robotically, and no
problems developed postoperatively. None of our
patients developed urethral stricture or bladder neck
contracture.
Positive surgical margin (PSM) was detected in
14 patients (20%) (Table 3). In our series, 4 patients
had biochemical recurrence with serum prostate
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Table 1. Preoperative patient characteristics in patients who underwent robot assisted
laparoscopic radical prostatectomy (RALRP) at our institution.
Patients (n)

70

Mean patient age (year)

62 ± 6 (range, 43-73)

Mean BMI (kg/m2)

27.5 ± 8.9 (kg/m2) (range, 20-39)

Mean serum PSA (ng/mL)

8.5 ± 5.9 (ng/mL) (range, 0.89-27)

Mean prostate volumes (cc)

52.4 ± 16.4 (cc) (range, 18-100)

Prostate biopsy Gleason Scores, n (%)
3+3
4+3
3+4
4+4
4+5
5+4
Clinical stage, n (%)
cT1c
cT2a
cT2b
Mean ASA score
Mean preoperative IIEF score
Preoperative mean IPSS

48 (68.6)
4 (5.7)
9 (12.9)
7 (10)
1 (1.4)
1 (1.4)

51 (72.8)
14 (20.0)
5 (72.0)
2
35.4 ± 23.3 (range, 5-75)
13 ± 6.9 (range, 0-28)

BMI: body mass index, PSA: prostate specific antigen, ASA: American Society of
Anesthesiologists, IIEF: International Index of Erectile Function, IPSS: International
Prostate Symptom Score.
Table 2. Operative measures of patients who underwent RALRP at our institution. APA: accessory
pudendal artery, NVB: neurovascular bundle, LND: lymph node dissection.
Mean surgery (console) time (including bilateral extended
pelvic lymph node dissection in 14 patients)

214 ± 55.5 min (range, 60-380)

Estimated intraoperative blood loss

215 ± 227.3 cc (range, 0-1500)

Mean prostate weight measured postoperatively
APAs detected and preserved, n (%)
Overall
Unilateral
Bilateral

15 (21.4)
13 (18.6)
2 (2.8)

NVB-sparing technique, n (%)
Bilateral
Unilateral
Not performed

62 (88.5)
2 (2.9)
6 (8.6)

Mean dorsal vein ligation time (minutes)
Number of patients with extended pelvic LND, n (%)
Mean urethral catheter removal time (days)
Mean lodge drain removal time (days)
Mean follow-up (months)

1340

52.3 ± 16.4 g (range, 18-100)

6.5 ± 4.6 (range, 2-25)
14 (20.0)
11.6 ± 5.9 (range, 7-32)
2.9 ± 2.7 (range, 1-20)
7.1 ± 3.2 (range, 0.75-12)
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Table 3. Postoperative oncologic outcomes of patients who underwent RALRP at our institution.
Pathologic stage, n (%)
ASAP + HGPIN
pT0
pT2a
pT2b
pT2c
pT3a
pT3b

1 (1.4)
2 (2.8)
10 (14.3)
3 (4.3)
17 (24.3)
31 (44.3)
6 (8.6)

Gleason score, n (%)
2-6
7
8-10

41 (58.5)
19 (27.1)
6 (8.5)

PSM rate, n (%)
Overall
pT2
pT3

14 (20.0)
2 (6.7)
12 (32.4)

Follow-up
Biochemical recurrence, n (%)
Available patients, n (%)

1 month
2 (2.8)
65 (92.8)

3 month
1 (1.4)
58 (82.9)

6 month
0 (0)
41 (58.5)

9 month
1 (1.4)
21 (30)

1 year
0 (0)
1 (1.4)

ASAP: atypical small acinar proliferation, HPIN: high grade prostatic intraepithelial neoplasia,
PSM: positive surgical margin.

Table 4. Functional outcomes and quality of life evaluations of the patients who underwent RALRP at our institution. IIEFS:
International Index of Erectile Function Score, Pts: patients, Preop: preoperative.
Continence status
n (%)
Immediate
3-month
6-month
9-month
1-year

Total control
(No leakage)
49 (70)
43 (74.1)
38 (92.7)
20 (95.2)
1 (100.0)

1 pad/day

2-3 pads/day

8 (11.4)
11 (19.0)
2 (4.9)
1 (4.8)
0 (0)

2 (2.9)
3 (5.1)
1 (2.4)
0 (0)
0 (0)

Total
incontinence
11 (15.7)
1 (1.7)
0 (0)
0 (0)
0 (0)

Erectile function
IIEFS, mean ± SD
Available pts, n (%)
*Preop IIEFS ≤ 13
n = 18 (25.7%)
*Preop IIEFS 13-18
n = 6 (8.6%)
*Preop IIEFS ≥ 19
n = 46 (65.7%)

Preoperative
35.4 ± 23.3
70 (100.0)
6.3 ± 1.7
(n = 18)
16.3 ± 1.1
(n = 6)
47.6 ± 17.0
(n = 46)

3-month
8.4 ± 4.3
58 (82.9)
6.4 ± 2.1
(n = 16)
6.2 ± 2.4
(n = 5)
8.3 ± 5.8
(n = 37)

6-month
12.4 ± 8.5
41 (58.5)
6.4 ± 1.6
(n = 11)
13.3 ± 0
(n = 3)
13.2 ± 9.0
(n = 27)

9-month
17.8 ± 10.1
21 (30.0)
7.8 ± 2.7
(n = 7)
17.0 ± 3.5
(n = 3)
45.3 ± 9.9
(n = 11)

Quality of life

Do it again?
Yes/No
64/3
67 (95.7)

n/n
Available patients, n (%)

Life quality
Better-same/Worse
64/3
67 (95.7)

Available
patients
70 (100)
58 (82.9)
41 (58.5)
21 (30.0)
1 (1.4)

1-year
10 ± 0
1 (1.4)
10 ± 0
(n = 1)

Satisfaction
Happy/Unhappy
62/5
67 (95.7)
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specific antigen (PSA) levels between 0.27 and 4.69
ng/mL at 1-9 months of follow-up (Table 3). These
patients had the worst pathological features. The
pathological evaluation revealed bilateral tumors in
all of these patients. Pathological stages and grades
on final pathology were pT3 in 3 patients (Gleason
scores 4+4, 3+4, and 4+3) and pT3b in another
patient (Gleason score 5+4) also with pelvic LN
involvement. No patients had disease progression
during follow-up.
We saw 15 accessory pudendal arteries (APAs), all
of which were preserved (Table 2). All patients with
preoperative erectile function (IIEF score > 7) were
instructed to use oral phosphodiesterase-5 (PDE-5)
inhibitors after removal of the urethral catheter.
Of the 46 patients with mild erectile dysfunction
or no dysfunction (preoperative IIEF score was > 19)
37, 27, and 11 patients were examined at the 3-, 6-,
and 9-month follow-up with mean IIEF scores of 8.3
± 5.8 (range, 5-55), 13.2 ± 9.0 (range, 7-55), and 45.3
± 9.9 (range, 10-65), respectively, at each interval.
Improvements in the erectile function and urinary
continence of our patients are shown in Table 4 and
Figures 1 and 2.
Two patients with preoperative IIEF scores of 55
and 59 who did not benefit from oral PDE-5 inhibitor
use were prescribed intracavernosal alprostadil
injection therapy in the postoperative period with
satisfactory response.
100
90

Of the available 21 patients at the 9-month followup, 20 (95.2%) had total urine control (Table 4).
Functional outcomes (including erectile function and
urinary continence) and quality of life evaluations
of the patients who were underwent RALRP at our
institution are summarized in Table 4.
Discussion
We hypothesized that previous experience in LRP
is not necessary before starting RALRP. However,
having knowledge of the 3-dimensional anatomy of
the prostate and its surroundings is essential.
Incompatibility of clinical and pathological
stages of patients with localized PCa has been well
documented. Approximately 25%-40% of patients
with clinical stage T1c PCa have advanced pathological
stage and grade disease following RP (8-10). Firstly,
our results confirmed this observation. Despite the
fact that we included patients with clinically localized
PCa, pathology on final specimen showed that 52.9%
of our patients were upstaged to pT3a (n = 31,
44.3%) and pT3b (n = 6, 8.6%). Assessment of the
Gleason score on preoperative biopsies also does not
correctly reflect the final pathology. In the literature,
the Gleason score of standard sextant biopsy was
reported to correctly predict the Gleason score of the
RP specimen in about 50% of cases and the Gleason
score on preoperative extended 12-core biopsies
predicted the Gleason score on final pathology in

Total control
1 pad/day
2-3 pads/day
Total incontinence

50
45
40
35

70

IIEF Score

% of patients

80
60
50

20
10

30

5

20

0

10

Preoperative

Preop IIEFS: ≤13
Immediate

3month

6month

9month

1Follow-up
month

Figure 1. Postoperative urinary continence status of our patients
who underwent RALRP at our institution.
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25
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40

0

30

3-month

6-month

Preop IIEFS: 13-18

9-month

Followup

Preop IIEFS: ≥19

Figure 2. Presentation of preoperative and postoperative erectile
functions of our patients who underwent RALRP at
our institution due to their IIEFS. IIEFS: International
Index of Erectile Function Score.

A. E. CANDA, A. F. ATMACA, Z. AKBULUT, E. ASİL, M. KILIÇ, A. E. İŞGÖREN, M. D. BALBAY

70% of cases (11). In the presented series, Gleason
scores of 3+3 or less were assigned to 48 (68.6%)
of our patients preoperatively. However, the final
pathological evaluation confirmed only 42 (60%) of
these. Twelve (17.1%) of our patients were upgraded,
while 16 (22.9%) were downgraded according to the
final pathological evaluation.
To date several authors have reported their initial
and updated follow-up results on RALRP (6,1215). In our experience we included patients with
localized disease (cT1-2) preoperatively (Table 1).
Mean preoperative serum PSA was 8.5 ± 5.9 ng/mL.
However, pathological evaluation of the removed
prostate specimens revealed that 35 (50%) patients
had pT3 disease (Table 3).
Mean surgery (console) time was 214 ± 55.5 min,
including bilateral extended pelvic LN dissections
in 14 patients, which seems to be similar to the
previously published literature (3-6). Mean console
time was reported to be somewhere between 105 and
341.9 min by others, which is most probably related
to experience (3-6). Comparably, mean estimated
intraoperative blood loss was 215 ± 227.3 cc in
our series. Others reported similar results ranging
between 111 and 339 cc (3-6).
Although we selected smaller sized prostates
initially (mean 52.4 ± 16.4 cc) we included patients
with larger prostates after successfully performing
the first 40 cases. In the literature, Menon et al. and
Novara et al. reported that average prostate weight
and volume were 49.9 g (range, 13-220) and 35 mL
(range, 26-48.7), respectively, in their series (4,5).

reported a PSM rate of 5.7% following 200 RALRP
procedures, which decreased to 2.5% following
performing 500 procedures (13,15). Our PSM rate
was 6.7% for patients with organ-confined disease in
our initial experience (Table 3).
Concerning pT3 disease, Ahlering et al. reported
a PSM rate of 62.5% following 50 RALRP procedures
(12), which decreased to 32% following performing
150 procedures (14). Similarly, Patel et al. reported a
PSM rate of 26% following 200 RALRP procedures,
which decreased to 13.8% following performing 500
procedures (13,15). Our PSM rate was 32.4% for pT3
disease in our initial experience (Table 3).
Preservation of the NVBs was performed in
patients with cT1c–T2a disease, a biopsy Gleason
score less than or equal to 7, a preoperative IIEF
score greater than 26, if NVBs were not stuck on the
prostate during dissection, and in patients without
significant comorbidities. We performed bilateral
NVB preservation in 64 patients in our series (Table
2). We performed interfascial NVB preservation on
the tumor side and intrafascial NVB preservation
on the nontumor-bearing side of the prostate. All
patients with pT3 disease had sufficient erectile
function preoperatively (mean preoperative IIEF
score: 35.4 ± 23.3) and requested their NVBs to be
preserved before the surgery.

Ahlering et al. and Patel et al. reported their
PSM rates as 35.5% (n = 45) and 10.5% (n = 200),
respectively, in their initial RALRP experience (12,13).
Increased experience seems to have a positive impact
on the PSM rates in performing RALRP. PSM rates
decreased to 20.4% (n = 200) and 9.3% (n = 1500),
respectively, in their series with inclusion of a larger
number of patients (6,14). Overall PSM rate was 20%
in our series (Table 3), which seems reasonable and
comparable to those of others.

The overall average percentage of return to
baseline sexual function was 51%, 58%, 66%, and 80%
at 1, 3, 6, and 12 months, respectively, as reported by
Mikhail et al. in a series of 100 RALRP patients (3).
Other authors with larger series of RALRP patients
reported their potency rates between 70% and 85%
at 1-year follow-up (2,6). Postoperative potency
rates of our series are summarized in Table 4 and
Figure 2. A dip at the 3-month follow-up occurred
regarding the postoperative IIEF scores in Figure 2,
which increased to almost preoperative values at the
9-month follow-up. This might be explained by the
neuropraxia that might have occurred during NVB
preservation, which needs time for recovery in the
postoperative period. All but 2 patients in our series
used PDE-5 inhibitors in the postoperative period.

Regarding organ-confined disease, Ahlering et al.
reported a PSM rate of 14.8% following 50 RALRP
procedures (12), which decreased to 6.5% following
performing 150 procedures (14). Likewise, Patel et al.

It is well established that preservation of the
NVBs has a crucial impact on erectile functional
recovery following radical prostatectomy. Moreover,
erectile tissue oxygenation supplied by the arteries
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irrigating the cavernous bodies including the APAs
seems to have an additional role in erectile function
(16) although Box et al. reported that sacrifice of
APAs in normally potent men during RALRP did
not impact potency (17). We detected 15 (21.8%)
APAs in our series and preserved all of them. We
think that preservation of APAs during RALRP may
favorably influence the recovery of sexual function in
the postoperative course (Table 1, Figure 3). APAs are
more frequently detected than previously reported
in the surgical literature, particularly following the
introduction of laparoscopic procedures (18). The
incidence of APAs was reported to vary between 4%
and 70% (18).
We performed the vesicourethral anastomosis by
using a running suture, as defined by Van Velthoven
et al. (19). We randomized our patients prospectively
for performing or not performing a posterior
reconstruction following the principles described by
Rocco et al. (20) before vesicourethral anastomosis
for a parallel study yet to be completed in which we
are planning to evaluate the impact of performing
posterior reconstruction, the results of which will be
discussed in the future.
The average percentage of return to baseline
urinary function was reported as 52%, 70%, 79%,
and 84% at 1, 3, 6, and 12 months, respectively, by
Mikhail et al. in a series of 100 RALRP patients
(3). Several RALRP series with large numbers of
patients reported excellent continence outcomes of
Pubic bone

Prostate
Figure 3. Accessory pudendal artery detected and preserved
during performing RALRP in one of our patients
(arrow).
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90%-95% by defining continence as no pad usage or
use of one safety pad/day in their series (2,6,21). In
our experience, immediate total urine control was
achieved in 70% of the cases in the postoperative
period (Table 4). At the 9-month follow-up this rate
increased to 95.2% (Table 4).
Diminished hospitalization periods are notable
in almost all RALRP series. A range of 1-6 days was
reported as the hospital stay in the large series from
the USA and Europe (3-6). In our experience, mean
lodge drain removal time was 2.9 ± 2.7 days when
patients were fit to go home (Table 2). Mean urethral
catheter removal time was 11.6 ± 5.9 days in our
initial experience, while others reported a median/
mean of 5 (range, 4-7), 6.3 ± 2.7 (range, 4-26), 4-7,
and 6.3 days (3-6).
Recently, Agarwal et al. reported the safety
profile of RALRP including 3317 patients (22).
They concluded that RALRP is a safe operation,
with an overall complication rate of 9.8% and most
complications occurred within 30 days of surgery.
In a series of 4400 consecutive RALRP patients,
Kheterpal et al. identified rectal injuries in 10
patients (0.2%) (23). Of these 10 patients, 9 had
an uneventful postoperative course and 1 patient
developed a rectourethral fistula and was treated
with colostomy. In our limited experience, we had
to switch to open surgery in only one patient (1.4%),
due to intraoperative deep acidosis development.
Additionally, rectal injury occurred in one patient
(1.4%), which we repaired robotically. None of our
patients developed urethral stricture or bladder neck
contracture in the follow-up.
Lastly, quality of life is a very important issue in
patients who undergo surgery. In our series, most
of our patients were happy and satisfied (92.5%)
with the outcomes of their RALRP procedures with
decreased postoperative pain and better cosmetic
results compared to open surgery.
In our series, we also demonstrated that
accessory pudendal arteries could easily be detected
and preserved by RALRP (24). Additionally, it is
important to state that robotic malfunction might
occur during the robotic approach; therefore, the
ability of the surgeon to complete this procedure
either laparoscopically or by the open approach
is important (25). A surgical robot could also be
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used to perform more than one abdominal surgical
procedure in the same session as we did in one of our
case that included RALRP and cholecystectomy (26).
The weaknesses of our study are as follows. We did
not compare our results in robotics and open RP since
robotic surgeons are doing the robotic procedures
while less experienced surgeons are doing the open
procedures. We also did not compare historic results
with the present study since they are not comparable.
Lastly, our follow-up in robotic cases was too short to
allow us to make a conclusion about the biochemical
recurrence rate.
In this report, we have presented our initial
experience on RALRP. All procedures were
performed by one of us (MDB) who had no previous
experience in performing LRP but with a great
experience in open RP and excellent understanding

of the surgical anatomy of the prostate and its
surroundings. Oncological and functional outcomes
in our series are comparable to those of most
experienced surgeons in RALRP. We therefore think
that gaining laparoscopic experience is not a must
before starting a robotic program for prostate cancer
surgery. However, we must emphasize that any
surgeon planning to go into robotic surgery has to
have a very good understanding of surgical anatomy.
We also concluded that clinical staging and any of
the parameters including serum PSA, digital rectal
examination, and biopsy Gleason score never reflect
the pathological status of the patients correctly at
least in half of our patients presented in this series.
Therefore, surgeons should discuss this issue with
their patients beforehand and inform them about the
probability of giving adjuvant treatments.
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